SCHEMBL1709933

SCHEMBL1709933

CC(C)(C)OC(=O)NCc1ncc2n1CCNC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
GFER P55789 3/20 0.42
L3MBTL1 Q9Y468 4/20 0.39
HSD17B10 Q99714 1/20 0.39
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
CA12 O43570 1/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709932 0.73 NPFFR1 (0.45) KDM4ELMNAGFERL3MBTL1HSD17B10
SCHEMBL28523399 0.71 TAAR1 (0.44) KDM4ELMNAGFERL3MBTL1MAPT
SCHEMBL24120598 0.68 SMN1; SMN2 (0.52) LMNAL3MBTL1HSD17B10CA1CA2
SCHEMBL30097054 0.67 L3MBTL1 (0.38) KDM4ELMNAGFERL3MBTL1CA1
SCHEMBL26144123 0.67 L3MBTL1 (0.38) KDM4ELMNAGFERL3MBTL1CA1
SCHEMBL8748416 0.67 CACNA1H (0.48) KDM4ELMNAGFERL3MBTL1HSD17B10
SCHEMBL27340643 0.67 CHRM3 (0.42) KDM4ELMNAGFERL3MBTL1CA1
SCHEMBL24533500 0.67 SIGMAR1 (0.48) KDM4ELMNAL3MBTL1ALDH1A1MAPT
SCHEMBL7237474 0.67 NOS2 (0.42) KDM4ELMNAL3MBTL1JAK2JAK1
SCHEMBL6447563 0.66 NAMPT (0.55) KDM4EL3MBTL1CA1CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 KDM4E 3815/4885LMNA 2043/4885GFER 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.